High- and low-risk human papillomavirus (HPV) type profiles in HPV-DNA-positive participants
Anogenital wart participants (n=108) | Male urethritis syndrome participants (n=56) | Voluntary counselling and testing/asymptomatic participants (n=50) | All (n=214) | |||||
N | % | N | % | N | % | N | % | |
No of HPV+ participants | 108 | 100.0 | 27 | 48.2 | 31 | 62.0 | 166 | 77.6 |
No of LR HPV+ | 108 | 100.0 | 22 | 81.5 | 28 | 90.3 | 158 | 95.2 |
No of HR HPV+ | 74 | 68.5 | 13 | 48.1 | 20 | 64.5 | 107 | 64.5 |
No of LR HPV+ only | 34 | 31.5 | 14 | 51.9 | 11 | 35.5 | 59 | 35.5 |
No of HR HPV+ only | 0 | 0.0 | 5 | 18.5 | 3 | 9.7 | 8 | 4.8 |
No of combined HR and LR HPV+ | 74 | 68.5 | 8 | 29.6 | 17 | 54.8 | 99 | 59.6 |
Multiple HPV genotypes | 95 | 88.0 | 15 | 55.6 | 25 | 80.7 | 135 | 81.3 |
No of HPV type 6/11 | 104 | 96.3 | 5 | 18.5 | 11 | 35.5 | 120 | 72.3 |
No of HPV type 16/18 | 32 | 29.6 | 6 | 22.2 | 8 | 25.8 | 46 | 27.7 |
No of HPV type 16/18 with another HR HPV type | 25 | 23.4 | 2 | 6.9 | 7 | 22.6 | 34 | 20.4 |
No of HPV type 6/11 and/or 16/18 | 106 | 98.1 | 11 | 40.7 | 17 | 54.8 | 134 | 80.7 |
Percentages calculated with respect to total HPV-positive participants.